Share information
246.60 €
-2.14 %
20/03/2026 17:36
-2.14 %
Open
High
Low
Volume
252.00 €
254.50 €
243.90 €
589,434
Latest News
20-Mar-2026
Acquisition of own shares
13-Mar-2026
Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees
11-Mar-2026
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
03-Mar-2026
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody